Skip to main content

Table 2 Practical issues about CGRP(r) MoAbs versus other migraine preventive treatments with established efficacy

From: How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

  CGRP(r) MoAbs Antiepileptics β-blockers OnabotulinumtoxinA
Route of administration Intravenous or subcutaneous injection Oral Oral Intramuscular
Dosing frequency Monthly or quarterly ≥1 daily ≥ 1 daily Quarterly
Adverse effects Rare Common Infrequent Rare
Pregnancy and nursing Contraindicated Contraindicated Possible with caution in the first trimester of pregnancy Not recommended during breastfeeding Contraindicated
Costs High Low Very low Medium
  1. CGRP(r) indicates Calcitonin gene-related peptide (receptor), MoAbs Monoclonal antibodies